No changes in striatal dopamine transporter in antidepressant-treated patients with major depression

International Clinical Psychopharmacology

Volumn 28, Issue 3, 2013, Pages 141-144

  Wu, Cheng Kuan ^a   Chen, Chin Kao ^a,b,d   Chen, Po See ^a,b,d   Chiu, Nan Tsing ^c   Yeh, Tzung Lieh ^a,b   Hui Lee, I ^a,b   Yang, Yen Kuang ^a,b  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^b Addiction Research Center   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

antidepressant; dopamine transporter; major depressive disorder; single photon emission computed tomograph; TRODAT 1

Indexed keywords

[2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M; DOPAMINE TRANSPORTER; FLUOXETINE; PAROXETINE; SERTRALINE; VENLAFAXINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CORPUS STRIATUM; DISEASE DURATION; FEMALE; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MALE; MENTAL PATIENT; NEUROIMAGING; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; CORPUS STRIATUM; DEPRESSIVE DISORDER, MAJOR; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; MALE; MIDDLE AGED; ORGANOTECHNETIUM COMPOUNDS; PSYCHIATRIC STATUS RATING SCALES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME; TROPANES;

EID: 84875764680     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0b013e32835ebcd7     Document Type: Article

References (24)

1. Albert PR, Lemonde S (2004). 5-ht1a receptors, gene repression, anddepression: guilt by association. Neuroscientist 10:575-593.
2. Argyelan M, Szabo Z, Kanyo B, Tanacs A, Kovacs Z, Janka Z, et al. (2005).Dopamine transporter availability in medication free and in bupropion treateddepression: a 99mtc-trodat-1 spect study. J Affect Disord 89:115-123.
3. Brunswick DJ, Amsterdam JD, Mozley PD, Newberg A (2003). Greater availabilityof brain dopamine transporters in major depression shown by [99m tc]trodat-1 spect imaging. Am J Psychiatry 160:1836-1841.
4. Charney DS (1998). Monoamine dysfunction and the pathophysiology andtreatment of depression. J Clin Psychiatry 59 (Suppl 14):11-14.
5. Chen PS, Yeh TL, Lee IH, Lin CB, Tsai HC, Chen KC, et al. (2011). Effects ofc825t polymorphism of the gnb3 gene on availability of dopamine transporterin healthy volunteers-a SPECT study. Neuroimage 56:1526-1530.
6. Damsa C, Bumb A, Bianchi-Demicheli F, Vidailhet P, Sterck R, Andreoli A, et al.(2004). 'Dopamine-dependent' side effects of selective serotonin reuptakeinhibitors: a clinical review. J Clin Psychiatry 65:1064-1068.
7. Di Matteo V, De Blasi A, Di Giulio C, Esposito E (2001). Role of 5-ht(2c)receptors in the control of central dopamine function. Trends Pharmacol Sci22:229-232.
8. Dremencov E, Weizmann Y, Kinor N, Gispan-Herman I, Yadid G (2006).Modulation of dopamine transmission by 5ht2c and 5ht3 receptors: a rolein the antidepressant response. Curr Drug Targets 7:165-175.
9. Dunlop BW, Nemeroff CB (2007). The role of dopamine in the pathophysiology ofdepression. Arch Gen Psychiatry 64:327-337.
10. Gordon I, Weizman R, Rehavi M (1996). Modulatory effect of agents active in thepresynaptic dopaminergic system on the striatal dopamine transporter. Eur JPharmacol 298:27-30.
11. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry23:56-62.
12. Hwang WJ, Yao WJ, Wey SP, Ting G (2004). Reproducibility of 99mtc-trodat-1spect measurement of dopamine transporters in Parkinson's disease. J NuclMed 45:207-213.
13. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT(2008). Initial severity and antidepressant benefits: a meta-analysis of datasubmitted to the food and drug administration. PLoS Med 5:e45.
14. Kugaya A, Seneca NM, Snyder PJ, Williams SA, Malison RT, Baldwin RM, et al. (2003). Changes in human in vivo serotonin and dopamine transporteravailabilities during chronic antidepressant administration. Neuropsychopharmacology28:413-420.
15. Kung MP, Stevenson DA, Plossl K, Meegalla SK, Beckwith A, Essman WD, et al. (1997). [99mtc]trodat-1: a novel technetium-99mcomplex as a dopamine transporter imaging agent. Eur J Nucl Med 24:372-380.
16. Laasonen-Balk T, Kuikka J, Viinamaki H, Husso-Saastamoinen M, Lehtonen J, Tiihonen J (1999). Striatal dopamine transporter density in major depression.Psychopharmacology (Berl) 144:282-285.
17. Meyer JH, Kruger S, Wilson AA, Christensen BK, Goulding VS, Schaffer A, et al.(2001). Lower dopamine transporter binding potential in striatum duringdepression. Neuroreport 12:4121-4125.
18. Moncrieff J, Kirsch I (2005). Efficacy of antidepressants in adults. BMJ 331:155-157.
19. Morelli E, Moore H, Rebello TJ, Gray N, Steele K, Esposito E, et al. (2011).Chronic 5-ht transporter blockade reduces DA signaling to elicit basalganglia dysfunction. J Neurosci 31:15742-15750.
20. Murray CJL, Lopez AD (1996). The global burden of disease. Cambridge, MA: Harvard University Press.
21. Nestler EJ, Carlezon WA Jr. (2006). The mesolimbic dopamine reward circuit indepression. Biol Psychiatry 59:1151-1159.
22. Nutt DJ (2006). The role of dopamine and norepinephrine in depression andantidepressant treatment. J Clin Psychiatry 67 (Suppl 6):3-8.
23. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al.(1998). The Mini-International Neuropsychiatric Interview (m.I.N.I.): thedevelopment and validation of a structured diagnostic psychiatric interviewfor DSM-IV and ICD-10. J Clin Psychiatry 59 (Suppl 20):22-33, quiz 34-57.
24. Yang YK, Yeh TL, Yao WJ, Lee IH, Chen PS, Chiu NT, et al. (2008). Greateravailability of dopamine transporters in patients with major depression-adual-isotope spect study. Psychiatry Res 162:230-235.